Onkológia 5/2021

Enfortumab vedotin in advanced urothelial carcinoma treatment

This review is devoted to enfortumab vedotin, a conjugate of anti-nectin 4 monoclonal antibody and the microtubule inhibitor monomethyl auristatin E. In addition to the mechanism of action and pharmacokinetics, the article also provides an overview of the most important results of phase 1 – 3 studies in patients with inoperable advanced urothelial carcinoma pretreated with chemotherapy based on platinum and immunotherapy, as well as the management of its the most common side effects. Due to significant differences in the key parameters (survival, objective responses) compared to standard chemotherapy and an acceptable toxicity profile, enfortumab vedotin has also become a third-line alternative treatment according to ESMO guidelines. The early phase study with enfortumab vedotin in combination with pembrolizumab in untreated cisplatin unfit patients with advanced urothelial carcinoma also shows promising results.

Keywords: enfortumab vedotin, efficacy, toxicity, advanced urothelial carcinoma, resistance to platinum